| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 01/30/2002 | EP1175888A2 Topical compositions comprising glycosylated hydroxystilbenes and their uses |
| 01/30/2002 | EP1175504A1 Dna encoding the human vanilloid receptor vr1 |
| 01/30/2002 | EP1175503A1 49 human secreted proteins |
| 01/30/2002 | EP1175490A2 Tyrosine kinase substrate (tks) proteins |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175445A1 Specific antibodies and antibody fragments for tgfbeta1 |
| 01/30/2002 | EP1175442A2 Osteopontin-derived chemotactic and inhibitory agents and uses therefor |
| 01/30/2002 | EP1175417A1 Substituted benzolactam compounds |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175402A1 Piperidine derivatives useful as ccr5 antagonists |
| 01/30/2002 | EP1175401A1 Piperazine derivatives useful as ccr5 antagonists |
| 01/30/2002 | EP1175246A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
| 01/30/2002 | EP1175235A1 Modified protein matrices |
| 01/30/2002 | EP1175223A2 Methods and compositions for modulating an immune response |
| 01/30/2002 | EP1175214A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 01/30/2002 | EP1175213A2 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 01/30/2002 | EP1045681A4 METHOD AND COMPOSITIONS FOR $i(IN SITU) FORMATION OF PROTECTIVE AND/OR MEDICATED FILMS ON BODY TISSUE |
| 01/30/2002 | EP0896521A4 Composition, barrier film, and method for preventing contact dermatitis |
| 01/30/2002 | EP0891187B1 Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents |
| 01/30/2002 | EP0564502B1 Tissue sealant and growth factor containing compositions that promote accelerated wound healing |
| 01/30/2002 | CN1333767A Aromatic heterocyclic compounds as antiinflammatory agent |
| 01/30/2002 | CN1333757A Quinazoline derivatives as medicaments |
| 01/30/2002 | CN1333754A Benzoheterocycles and their use as MEK inhibitors |
| 01/30/2002 | CN1333036A Hair-growing powder medicine and preparation process thereof |
| 01/30/2002 | CN1333034A Skin disease ointment and preparation process thereof |
| 01/30/2002 | CN1333033A Medical composition for treating leukoderma |
| 01/30/2002 | CN1333031A Agent for hair growth promoting, anti hair whitening, baldness proof dandruff eliminating |
| 01/30/2002 | CN1333022A Turtle oil, trionxy oil, composition containing same and usage thereof |
| 01/30/2002 | CN1333015A Composition containg three-position non-substituted flavylium and organic modified polyorganosiloxane for coloring skin |
| 01/29/2002 | US6342602 Bind specifically or selectively to rar-alpha receptors |
| 01/29/2002 | US6342584 Antiproliferative, anticarcinogenic, antitumor, antiinflammatory, and antimetastasis agents; diabetes, restenosis, rheumatoid arthritis treatment; genetic engineering |
| 01/29/2002 | US6342537 Gel for treatment of skin diseases and for disinfection of the skin |
| 01/29/2002 | US6342521 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 01/29/2002 | US6342509 Antiasthmatics, antihistamines or bronchodialators |
| 01/29/2002 | US6342505 Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-β1 |
| 01/29/2002 | US6342502 Thieno[2,3-d]pyrimidine diones and their use in the treatment of reversible obstructive airways diseases |
| 01/29/2002 | US6342487 Compositions containing at least one farnesyl transferase inhibitor and at least one topoisomerase inhibitor and compositions containing at least one farnesyl transferase inhibitor and at least one taxoid |
| 01/29/2002 | US6342254 Anti-proliferative preparations |
| 01/29/2002 | US6342238 Organogel comprising an oxidation-sensitive hydrophilic compound, and uses thereof, in particular cosmetic uses |
| 01/29/2002 | CA2237780C Reduction of hair growth |
| 01/29/2002 | CA2107568C Use of sphingolipids in the preparation of a cosmetic or dermato-pharmaceutical composition for the protection of skin and hair against the harmful effects of atmospheric pollution |
| 01/29/2002 | CA2063127C Reduction in cutaneous atrophy |
| 01/29/2002 | CA2031368C Composition comprising non-steroidal non-inflammatory agent and effectively non-antibacterial tetracycline |
| 01/28/2002 | CA2354110A1 Use of agonists of the prostaglandin ep 3 receptor as a cosmetic agent to mitigate, reduce or stop hair growth |
| 01/28/2002 | CA2354109A1 Use of non-prostanoid agonists of prostaglandin e2 and/or ep-4 receptors as a cosmetic agent for mitigating, reducing or stopping hair loss |
| 01/28/2002 | CA2354108A1 Use of agonists of the prostaglandin ep 3 receptor to mitigate, reduce or stop hair growth in cosmetic preparations |
| 01/28/2002 | CA2354107A1 Topical compounds including glucosyl hydroxystilbenes and uses |
| 01/24/2002 | WO2002006821A2 Antimicrobial agent |
| 01/24/2002 | WO2002006492A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 01/24/2002 | WO2002006351A1 Drugs or cosmetics |
| 01/24/2002 | WO2002006349A1 Gel compositions containing metronidazole |
| 01/24/2002 | WO2002006316A2 Alpha-msh related compounds and methods of use |
| 01/24/2002 | WO2002006293A1 Matrix metalloproteinase inhibitors |
| 01/24/2002 | WO2002006284A1 Indoloquinazolinones |
| 01/24/2002 | WO2002006271A1 Pyrimidine derivatives |
| 01/24/2002 | WO2002006270A1 Novel 6-heteroarylphenanthridines |
| 01/24/2002 | WO2002006242A2 5-substituted 2-aryl-4-pyrimidinones |
| 01/24/2002 | WO2002006236A1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 01/24/2002 | WO2002006225A1 Preventives or remedies for atopic dermatitis |
| 01/24/2002 | WO2002006224A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | WO2002006222A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 01/24/2002 | WO2002006213A2 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 01/24/2002 | WO2002006205A1 Method for preparing a fatty substance ester and use thereof in pharmaceutics, cosmetics or food industry |
| 01/24/2002 | WO2002005839A1 Agent for inhibiting adhesion of the pathogenic flora of the skin |
| 01/24/2002 | WO2002005834A2 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions |
| 01/24/2002 | WO2002005830A2 Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof |
| 01/24/2002 | WO2002005828A1 Compositions and methods for the treatment of skin damage |
| 01/24/2002 | WO2002005824A1 USE OF 2α-METHYL-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH |
| 01/24/2002 | WO2002005823A2 USE OF 2-METHYLENE-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH |
| 01/24/2002 | WO2002005809A1 Dermal for amino laevulinic acid |
| 01/24/2002 | WO2002005775A1 Composition, in particular cosmetic, containing dhea and/or a chemical or biological precursor or derivative thereof, and a metalloproteinase inhibitor |
| 01/24/2002 | WO2002005774A1 Use of extracted soluble protein fractions |
| 01/24/2002 | WO2002005773A1 Topical treatment of skin |
| 01/24/2002 | WO2002005755A1 Cosmetic compositions for reducing and method of using the same |
| 01/24/2002 | WO2002005662A1 Physiologically functional foods or cosmetics containing sphingoglycolipids and processes for their production |
| 01/24/2002 | WO2001064750A3 Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis |
| 01/24/2002 | WO2001060833A3 Motilide compounds |
| 01/24/2002 | WO2001060814A3 Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 01/24/2002 | WO2001053324A3 Novel haptotactic peptides |
| 01/24/2002 | WO2001052892A3 Jak/stat pathway inhibitors and the uses thereof |
| 01/24/2002 | WO2001049822A3 Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy |
| 01/24/2002 | WO2001046258A3 Transporters and ion channels |
| 01/24/2002 | WO2001038305A3 Novel il-8 receptor antagonists |
| 01/24/2002 | WO2001036005A3 Targeted delivery of therapeutic and diagnostic moieties |
| 01/24/2002 | WO2001034768A3 15 human secreted proteins |
| 01/24/2002 | WO2001032910A3 27 human secreted proteins |
| 01/24/2002 | WO2001023357A3 Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists |
| 01/24/2002 | WO2001019860A3 Proteins associated with cell differentiation |
| 01/24/2002 | WO2001017564A3 Enzyme inhibitors |
| 01/24/2002 | WO2001016290A3 Dna encoding the human serine protease eos |
| 01/24/2002 | WO2001014405A3 Methods of obtaining 2-methoxyestradiol of high purity |
| 01/24/2002 | WO2001012819A3 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 01/24/2002 | WO2001000655A3 Therapeutic peptides derived from subsequences of bpi |
| 01/24/2002 | US20020010949 Cloning using donor nuclei from differentiated fetal and adult cells |
| 01/24/2002 | US20020010337 Stilbene compounds comprising an adamantyl group, compositions and methods thereof |
| 01/24/2002 | US20020010316 Thiazole derivatives |
| 01/24/2002 | US20020010315 Treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. |
| 01/24/2002 | US20020010196 Antiulcer agents, treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison syndrome |
| 01/24/2002 | US20020010190 N-heterocyclic derivatives as NOS inhibitors |
| 01/24/2002 | US20020010185 Anticarcinogenic agents |